Akanksha Sharma, MD
Neurology · San Francisco, CANPI 1124361712
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Novocure Inc. accounts for 73.0% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2023 at $7,585 and has fallen 95.7% since, to $327 in 2025.
Across 43 payments — averaging $256.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure Inc.$8K
- Servier Pharmaceuticals LLC$2K
- Jazz Pharmaceuticals Inc.$101
- Lilly USA, LLC$74
- Daiichi Sankyo Inc.$63
- Octapharma USA, Inc.$59
- plus $432 from 14 others
Across 112 payments — averaging $1840.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novocure GmbH$103K
- Incyte Corporation$103K
What the payments were for
- Consulting fees$2,14619%
- Speaking & faculty fees$6,02555%
- Travel & lodging$1,29512%
- Food & beverage$1,57314%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure Inc. | 13 | $8,053 |
| Servier Pharmaceuticals LLC | 3 | $2,255 |
| Jazz Pharmaceuticals Inc. | 1 | $101 |
| Lilly USA, LLC | 3 | $74 |
| Daiichi Sankyo Inc. | 3 | $63 |
| Octapharma USA, Inc. | 2 | $59 |
| E.r. Squibb & Sons, L.L.C. | 2 | $53 |
| AstraZeneca | 2 | $52 |
| Bayer | 2 | $48 |
| Neurelis, Inc. | 2 | $46 |
| CSL Behring | 1 | $34 |
| Seagen Inc. | 1 | $32 |
| Novartis | 1 | $30 |
| Biogen | 1 | $28 |
| Merck | 1 | $22 |
| Foundation Medicine, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $19 |
| Cumberland Pharmaceuticals, Inc. | 1 | $17 |
| Amgen | 1 | $15 |
| ADC Therapeutics America, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,039 in reported general payments places this provider in the 75th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BriviactBrivaracetam | 12 | $16,388 |
| Fentanyl | 11 | $560 |
| Lacosamide | 15 | $437 |
| Dexamethasone | 11 | $203 |
| Oxycodone Hcl | 12 | $197 |
| Gabapentin | 11 | $103 |
Paid to pharmacies, not to this prescriber.
Other neurology in San Francisco
- S Claiborne JohnstonSan Francisco$576K
- Armen MoughamianSan Francisco$554K
- Scott ZamvilSan Francisco$447K
- Bruce CreeSan Francisco$412K
- Kenneth LaxerSan Francisco$379K
- Jonathan KatzSan Francisco$294K
- Nada HindiyehSan Francisco$268K
- Douglas GoodinSan Francisco$227K
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.